Trade-Ideas LLC identified




) as a strong and under the radar candidate. In addition to specific proprietary factors, Trade-Ideas identified Inogen as such a stock due to the following factors:

  • INGN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $12.7 million.
  • INGN has traded 36.82090000000000173940861714072525501251220703125 options contracts today.
  • INGN is making at least a new 3-day high.
  • INGN has a PE ratio of 84.
  • INGN is mentioned 0.84 times per day on StockTwits.
  • INGN has not yet been mentioned on StockTwits today.
  • INGN is currently in the upper 20% of its 1-year range.
  • INGN is in the upper 35% of its 20-day range.
  • INGN is in the upper 45% of its 5-day range.
  • INGN is currently trading above yesterday's high.

'Strong and Under the Radar' stocks tend to be worthwhile stocks to watch for a variety of factors including historical back testing and price action. Market technicians refer to such stocks as being in an accumulation phase before a mark-up and peak. Traders and hedge funds have frequently found that these types of stocks continue to build a solid price base and then ultimately spike higher and peak when others 'discover' how good the stock is performing. By leveraging the social discovery aspect of StockTwits we are highlighting stocks that don't currently receive much attention from retail investors, but we suspect may soon garner more attention.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in INGN with the Ticky from Trade-Ideas. See the FREE profile for INGN NOW at Trade-Ideas

More details on INGN:

Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. INGN has a PE ratio of 84. Currently there are 5 analysts that rate Inogen a buy, no analysts rate it a sell, and 1 rates it a hold.

The average volume for Inogen has been 252,500 shares per day over the past 30 days. Inogen has a market cap of $999.4 million and is part of the health care sector and health services industry. Shares are up 27.5% year-to-date as of the close of trading on Wednesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.


TheStreet Quant Ratings

rates Inogen as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including premium valuation and weak operating cash flow.

Highlights from the ratings report include:

  • The revenue growth came in higher than the industry average of 6.9%. Since the same quarter one year prior, revenues rose by 27.4%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • INGN's debt-to-equity ratio is very low at 0.00 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Along with this, the company maintains a quick ratio of 4.66, which clearly demonstrates the ability to cover short-term cash needs.
  • Looking at where the stock is today compared to one year ago, we find that it is not only higher, but it has also clearly outperformed the rise in the S&P 500 over the same period. Although other factors naturally played a role, the company's strong earnings growth was key. Looking ahead, the stock's rise over the last year has already helped drive it to a level which is relatively expensive compared to the rest of its industry, implying reduced upside potential.
  • Net operating cash flow has decreased to $4.78 million or 21.18% when compared to the same quarter last year. In conjunction, when comparing current results to the industry average, INOGEN INC has marginally lower results.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.